SUPERNUS PHARMACEUTICALS, INC. Assets, Fair Value Disclosure
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Assets, Fair Value Disclosure of $374.30 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Net Asset (Liability)
us-gaap:AssetsFairValueDisclosure · last filed 2026-08-03
- 2026-06-30: Assets, Fair Value Disclosure $374.30M.
- 2026-03-31: Assets, Fair Value Disclosure $386.37M.
- 2025-12-31: Assets, Fair Value Disclosure $310.82M.
- 2024-12-31: Assets, Fair Value Disclosure $454.25M.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $374.30M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $386.37M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $310.82M 10-Q · filed 2026-08-03 |
| 2024-12-31 | $454.25M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |